イタリア 原薬&中間体メーカー「Procos S.p.A.(プロコス社)」

最新事例紹介

Overview of Business & Key Attributes

We work hard to develop fruitful partnerships with pharmaceutical companies around the world.

Procos is a manufacturer of APIs and pharmaceutical intermediates for the healthcare industry. Calling on the technology and expertise that we have developed over many years, we provide customers with products and services of the highest quality. In addition to the contract manufacturing of APIs and intermediates, we also manufacture generic raw materials, while, of course, adhering to cGMPs.

Our plant just outside Milan houses over 300 m3 of stainless steel and glass line reaction containers in 110,000 m2 of space. All facilities at Procos are designed to meet cGMP quality control standards. At present, Procos regularly produces more than 30 types of APIs and intermediates. Many of theses products have chemical reactions featuring synthesis routes specially developed by Procos. Meanwhile, we continue to maintain optimum product quality through extremely rigid product manufacturing processes

Our products and services are a strong presence amongst pharmaceutical markets around the globe. We are moving to further develop our unique generic APIs and major intermediates, bringing them to markets the world over.

Examples of Recent Initiatives 1
Kilo Lab

We are also considering early-stage development projects and niche-market generic APIs, as well as scale-up strategies for new product launches.

Glass reaction containers (25L & 50 L) and Hastelloy containers (25 L & 50 L) allow for the automatic adjustment of temperature and churning speed. In addition, the potential of centrifugal machines, dryers, and pulverizing machines makes it seem like a miniature factory.

Examples of Recent Initiatives 2
Expansion of R&D and QCLabo

In recent years, we have expanded our laboratory space by 150% The additional space has been structured to house laboratory tables, analysis equipment and more, essentially doubling the size of our work area. Moreover, the new space has enabled greater operations efficiency, making it possible for us to expand both R&D and analysis staff in the future.
We also created a room dedicated to analysis methodology development, which features new equipment, such as UPLC-MS and NMR, that allowed us to bolster our facility's R&D capabilities.